Tiagabine

drugbox
IUPAC_name = (3"S")-1- [4,4-bis(3-methylthiophen-2-yl)but-3-enyl] piperidine-3-carboxylic acid

---

CAS_number = 115103-54-3
ATC_prefix = N03
ATC_suffix = AG06
PubChem = 60648
DrugBank = APRD00344
C = 20 |H = 25 |N = 1 |O = 2 |S = 2
molecular_weight = 375.55 g/mol
bioavailability = 90%
protein_bound = 96%
metabolism = Hepatic (CYP450 system)
elimination_half-life = 7-9 hours
excretion = Fecal and renal
pregnancy_category = B3 (Au), C (U.S.)
legal_status = POM (UK), ℞-only (U.S.)
routes_of_administration = Oral Tiagabine (pronEng|taɪˈæɡəbiːn] [http://www.umm.edu/altmed/drugs/tiagabine-125250.htm#Pronunciation] ) is an anti-convulsive medication produced by Cephalon and marketed under the brand name Gabitril. The drug was discovered at Novo Nordisk in Denmark in 1988. and was co-developed with Abbott. After a period of co-promotion, Cephalon licensed Tiagabine from Abbott/Novo and now are the exclusive producer. The medication is also used in the treatment of panic disorder as are a few other anticonvulsants.

Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, evidence is available that it operates as a selective GABA reuptake inhibitor.

Side effects

Tiagabine's most common side effects include confusion, difficulty speaking clearly/stuttering, mild sedation, and in doses over 8 mg, a tingling sensation (paresthesia) in the body's extremities, particularly the hands and fingers.

External links

* [http://www.gabitril.com/physicians/home/default.asp Gabitril] (manufacturer's website)